Masseter Jaw Slimming Treatment

Patients arrive at masseter consultation through three distinct doors. The first comes through the mirror: a person who has noticed their lower face is squarer than they want it to be, often with a more masculine outline that does not match their internal sense of how their face should look. The second comes through the dentist: a person who has been told they are clenching or grinding their teeth at night, who has woken with jaw pain or headaches, and whose dentist has suggested neuromodulator treatment as part of bruxism management. The third comes through both at once: hypertrophy and bruxism are physiologically related and frequently coexist.

The treatment is the same in each case. The conversation, the dosing and the expected timeline differ.

The masseter and what makes it interesting clinically

The masseter is one of the four muscles of mastication and one of the strongest muscles in the body relative to its size. It originates from the zygomatic arch, inserts into the angle of the mandible, and provides the bulk of the closing force in chewing. Like any skeletal muscle subjected to repeated heavy use, it can hypertrophy. Patients who chew tough foods consistently, who clench during the day or night, who have a history of orthodontic intervention, or who simply have a genetic predisposition to masseter prominence may develop visible muscle bulk that affects the outline of the lower face.

The mechanism by which neuromodulator addresses this is dual. In the short term, the muscle activity is reduced, and pain associated with clenching or grinding is relieved. In the longer term (months, with repeated treatment), the reduced activity leads to atrophy in the treated muscle, which translates into visible reduction in muscle bulk and a softer lower face contour. Both effects are reversible if treatment is stopped.

Bruxism and the dental relationship

Bruxism is involuntary clenching or grinding of the teeth, typically nocturnal but sometimes diurnal. It is associated with morning jaw pain, temporal headache, dental wear, restoration failure, temporomandibular joint pain, and sometimes a partner reporting audible grinding at night. The aetiology is multifactorial: stress, sleep architecture, malocclusion, lifestyle factors and individual variation all contribute. Conventional management includes occlusal splints (provided by a dentist), behavioural strategies, sleep hygiene, and where indicated, neuromodulator treatment of the masseter.

The published clinical evidence for masseter neuromodulator in bruxism is solid: dose ranges of 25 to 50 international units per side typically produce meaningful reduction in muscle activity, decrease in clench related pain, and patient-completed improvement in nocturnal symptoms. Lower doses (10 to 20 units per side) have also been shown to provide some symptomatic benefit in less severe presentations. The treatment does not replace appropriate dental management; it is part of a broader approach.

Masseter hypertrophy and the lower face contour

Masseter hypertrophy is the indication that brings most cosmetic patients to consultation. The clinical sign is visible bulging of the muscle when the patient bites down, often accompanied by a wider lower face outline at rest. The cosmetic goal is softening of this outline rather than complete muscle elimination. The functional goal is reduction of clench related symptoms where they coexist.

Onset of visible change is gradual. Reduction in muscle activity begins within a week of treatment and is established by two weeks. Visible reduction in bulk takes longer because muscle atrophy is a slower process. Most patients begin noticing visible change at four to six weeks, with the result becoming more pronounced over the following two months. The full effect of a single treatment is typically visible at three months. Repeated treatment over twelve to eighteen months produces cumulative reduction.

Dosing in this region

Conservative dosing for masseter is towards the lower end of the published range, typically 25 to 35 units per side at first treatment, with structured review at four to six weeks where dose can be adjusted upward at the next cycle if response has been insufficient. Some patients respond to lower doses, particularly those with mild bruxism without significant hypertrophy. Some patients with substantial hypertrophy may require doses towards the upper end of the range across multiple cycles before the desired contour change is achieved.

Going above 50 units per side is occasionally clinically appropriate but should not be a routine first treatment approach. Higher doses produce faster atrophy but also higher risk of side effects, including transient difficulty chewing tougher foods. The conservative approach errs in favour of preserving function, with the option to increase dose at the next cycle if needed.

What treatment involves

The treatment is performed in clinic in a single appointment of approximately twenty to thirty minutes. After consultation and consent, the practitioner palpates the masseter to identify the area of greatest bulk and the safe injection points (avoiding the parotid gland anteriorly and the masseteric vessels). The dose is divided across three to five injection points per side, placed within the muscle belly. Discomfort is brief and generally tolerated. There is no practical downtime. Patients return to normal activity immediately.

Onset of muscle relaxation begins within a week, with full relaxation at two weeks. Patients commonly notice within the first week that nocturnal clenching has reduced and that morning jaw discomfort has eased. The cosmetic effect (visible reduction in lower face squareness) takes longer and becomes evident over the subsequent weeks.

Side effects and what we monitor

Common side effects include brief tenderness at injection points, occasional bruising, transient difficulty chewing tougher foods (particularly at higher doses, particularly in the first few weeks), and rarely a feeling of the smile being slightly different during the relaxation phase as the surrounding muscles adjust. Most patients describe the experience as generally tolerated and the side effects as minor.

Less common effects include asymmetry, paradoxical bulging at the lower border of the muscle (an indicator of injection placement that needs adjustment at the next cycle), and very rarely allergic reactions. Sustained treatment over many years can produce changes in the appearance of the smile as adjacent muscles compensate for reduced masseter activity. These are discussed at consent and patients receive a direct contact for any post treatment concerns.

Duration and the maintenance rhythm

Onset of effect is at two weeks. Duration of muscle relaxation is typically four to six months at first treatment, sometimes longer with repeated treatment as cumulative atrophy reduces the dose required to maintain effect. The visible cosmetic change accumulates across multiple treatment cycles. Patients who have been treated consistently for several years often describe the maintenance rhythm as comfortable and unobtrusive, with the option to extend intervals once the desired contour has been achieved.

For patients whose primary indication is bruxism, the maintenance rhythm is determined by the return of clenching symptoms rather than by visible change. Patients sometimes find that nocturnal symptoms remain controlled longer than visible muscle activity, allowing extended intervals between treatments.

Who this treatment is not for

Several presentations look like masseter indications but warrant a different conversation. Visible squareness of the lower face that is primarily due to bony mandibular shape rather than muscle bulk will not respond to neuromodulator treatment, because the underlying contributor is skeletal rather than muscular. Patients with significant temporomandibular joint pathology may need referral to dentistry or maxillofacial speciality before cosmetic muscle treatment is considered. Patients with very thin overlying tissue may not be appropriate candidates because the visible result is harder to achieve.

Naming these distinctions at consultation is part of an honest plan. Patients who would not benefit from masseter neuromodulator treatment are better served by being told so clearly than by being offered a treatment that will not deliver what they hoped for.

AHPRA September 2025 considerations

The AHPRA guidelines for nonsurgical cosmetic procedures that came into force in September 2025 require an in person or video consultation with the prescribing practitioner each time a cosmetic injectable is prescribed. For masseter treatment with its longer maintenance interval, the consultation requirement applies to each treatment cycle. Suitability assessment must explicitly explore motivations and expectations, including the realistic timeline to visible change.

For masseter specifically, the September 2025 framework also reinforces the importance of distinguishing between cosmetic indication (hypertrophy, contour) and medical indication (bruxism, pain). Both are legitimate reasons for treatment but the conversation differs in emphasis and the documentation differs in framing.

Why we do not name the prescription product

Australian regulation prohibits the advertising of Schedule 4 prescription medicines to the public. That includes the brand names, abbreviations and hashtags associated with cosmetic injectable products. The TGA has been increasingly active in enforcing this provision in the cosmetic injectables sector. We can talk in clinical detail about the mechanism, dose ranges, response profile and safety considerations. We do not name brands or otherwise identify products to the public, because the law explicitly prohibits us from doing so.

How this fits with broader lower face planning

For patients whose concern is the visible outline of the lower face, masseter softening is sometimes one element of a broader plan that may include consideration of jawline definition (whether structural support of the mandibular border would complement the masseter softening), chin contour (whether modest projection would balance the change), or the platysma below (whether neck band activity is contributing to the lower face appearance). Each of these is its own clinical decision; none is a default add on.

The structured planning of the lower face is part of the C.O.R.E. Method approach. Consult, organise the plan, refine in stages, evaluate at each cycle. Masseter treatment is often the first step in this sequence because the visible change accrues over months and informs subsequent decisions.

Working with Corey

Corey Anderson is the only practitioner at Core Aesthetics. Registered with the Nursing and Midwifery Board of Australia since January 1996 (AHPRA NMW0001047575), Corey runs a one practitioner, low volume clinic in Oakleigh. For masseter treatment, the consistency of practitioner technique across years of repeated visits supports the kind of incremental dose calibration that produces stable, predictable contour change without functional compromise.

Patients see Corey at every visit. Treatment notes carry the dose, the placement detail and the response duration forward across years.

Cost framing

Pricing is straightforward. Masseter treatment is priced on the actual product and time involved, quoted in writing as part of the consultation. There is no surge pricing, no time limited promotional pricing and no loyalty discounting. Patients receive a written treatment plan that includes the realistic anticipated frequency of maintenance and the cumulative cost across the first twelve months.

Booking a consultation

Masseter consultation can be a stand alone appointment or part of a broader lower face conversation. The consultation is a clinical assessment in its own right, with no obligation to proceed in the same session. If treatment is appropriate, it can be performed in the same visit. Results vary between individuals.

Core Aesthetics operates from 12A Atherton Road, Oakleigh, in Melbourne south east. Booking is direct online or by contacting the clinic.

A note on the relationship between dental care and masseter treatment

Dentists and cosmetic injectors increasingly co manage bruxism. The dental contribution typically includes assessment of occlusion, fitting of an occlusal splint to protect the dentition, and management of dental wear or restoration. The cosmetic injector contribution is the muscular activity reduction that addresses the underlying clenching force. Patients who are managed by both disciplines typically have better outcomes than patients managed by either alone, particularly where bruxism has produced both functional symptoms and visible muscular hypertrophy. The conversation about referral pathways and shared care is part of the consultation when bruxism is the primary indication.

For patients whose dentist has specifically suggested neuromodulator treatment, the consultation is often shorter because the indication has already been clarified. For patients who arrive without a prior dental conversation, recommending a parallel dental review is often part of the treatment plan, particularly where dental wear or restoration failure is part of the picture.

On treatment intervals over the long term

Patients who continue masseter treatment across multiple years often find that the dose required to maintain the desired result decreases gradually as cumulative atrophy reduces baseline muscle bulk. The maintenance interval lengthens correspondingly. By the third or fourth year of consistent treatment, many patients have moved from a four monthly cycle to a six monthly cycle, and the dose per visit has reduced from the initial conservative starting point. This is part of why the treatment is sometimes described as front loaded: most of the visible change happens in the first twelve to eighteen months, with maintenance becoming progressively lighter touch.

For patients whose primary indication was bruxism, the same pattern applies for the functional symptoms. Less frequent treatment is sometimes adequate to maintain symptom control once the muscle activity baseline has been reset by the initial sustained treatment phase.

The cumulative pattern of front loaded treatment with progressively lighter maintenance is one of the features that makes masseter work clinically interesting compared to the more uniform retreatment intervals of upper face neuromodulator indications.

This pattern also informs how the cost discussion is framed at the start. Patients are not committing to a high frequency treatment for life. They are committing to a more intensive first phase, after which the treatment becomes lighter and less frequent if the response holds.

A note on patient experience over time

Patients who incorporate masseter treatment into a sustained plan often describe two parallel experiences. The functional one (less morning jaw pain, less nocturnal clenching, fewer headaches) is usually the first to appear and the easiest to evaluate. The cosmetic one (a softer lower face outline, a less prominent jaw angle, a face that reads as more rested) emerges more gradually and is sometimes pointed out by friends and family before the patient notices it themselves. The two effects together produce a treatment experience that is unusual in cosmetic injectables for combining medical and cosmetic benefit in a single, well evidenced intervention.